- Erratum
- Open access
- Published:
Erratum to: Dual HER2 blockade: preclinical and clinical data
Breast Cancer Research volume 16, Article number: 468 (2014)
Abstract
No abstract.
Erratum
After publication of our review [1], we noted errors to the legend of Figure 1B, C. The ado-trastuzumab-emtansine concentration should be 1 μg/ml instead of 1 mg/ml. The trastuzumab concentration should be 10 μg/ml instead of 10 mg/ml. The lapatinib concentration should be 10 μM instead of 10 mM (Please see Figure 1, a corrected version of the original Figure 1).
Dual blockade with antibody–drug conjugate and targeted therapy. (A) SCID Beige mice were injected with 1 million cells per mouse in the estrogen receptor-positive, human epidermal growth factor receptor (HER)-positive cell line called BT474-m1. These animals were randomized into six groups and treated with: vehicle control; trastuzumab (5 mg/kg once weekly); lapatinib (100 mg/kg daily); ado-trastuzumab-emtansine (TDM-1; 5 mg/kg weekly); trastuzumab (5 mg/kg once weekly) + lapatinib (100 mg/kg daily); or TDM-1 (5 mg/kg weekly) + lapatinib (100 mg/kg daily). Tumor volume fold-change will be measured twice weekly post treatment. (B), (C) BT474 and SKBR3 HER2-positive cell lines were treated with the following: vehicle control; TDM-1 (1 μg/ml); trastuzumab (10 μg/ml) + lapatinib (10 μM) 4); or TDM-1 (1 μg/ml) + lapatinib (10 μM). Cells were assessed for proliferation and apoptosis post treatment. *Data analyzed by one way analysis of variance followed by Tukey analysis for a pairwise comparison of different groups, P < 0.05. T, trastuzumab; L, lapatinib. Data from J Chang, unpublished data.
References
Patel TA, Dave B, Rodriguez AA, Chang JC, Perez EA, Colon-Otero G: Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res. 2014, 16: 419-10.1186/s13058-014-0419-5.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at 10.1186/s13058-014-0419-5
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
Rights and permissions
About this article
Cite this article
Patel, T.A., Dave, B., Rodriguez, A.A. et al. Erratum to: Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res 16, 468 (2014). https://doi.org/10.1186/s13058-014-0468-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s13058-014-0468-9